Aug 12 2010
Scientists at ChemImage, in association with a US-based medical research and treatment center, have conducted a research, which showed that the RMI (Raman Molecular Imaging) has significant potential in detecting prostate cancer progression. The RMI integrates molecular spectroscopy and digital imaging to study chemically different substances.
Scientists collected samples from 38 patients diagnosed with Gleason score 7 tumor prostate cancer. The samples were then evaluated by using the Raman Molecular Imaging. Half of the subjects had metastatic prostate cancer, while the other half showed no evidence of the disease post treatment.
The RMI differentiates the chemical variations of patients with metastatic prostate cancer in comparison to patients who showed no signs of prostate cancer.
ChemImage’s Vice President of Biomedical Research, John Maier, stated that the company plans to continue the study on prostate cancer and will explore RMI’s application in other types of cancers such as kidney and lung cancer.
Source: http://www.chemimage.com